Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Oct;51(10):725–730. doi: 10.1136/jcp.51.10.725

AIDS vaccine development: let a thousand flowers bloom.

J S Oxford 1, M Addawe 1, R Lambkin 1
PMCID: PMC500925  PMID: 10023333

Full text

PDF
725

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abimiku A. G., Franchini G., Tartaglia J., Aldrich K., Myagkikh M., Markham P. D., Chong P., Klein M., Kieny M. P., Paoletti E. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med. 1995 Apr;1(4):321–329. doi: 10.1038/nm0495-321. [DOI] [PubMed] [Google Scholar]
  2. Ahlers J. D., Dunlop N., Pendleton C. D., Newman M., Nara P. L., Berzofsky J. A. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses. 1996 Mar 1;12(4):259–272. doi: 10.1089/aid.1996.12.259. [DOI] [PubMed] [Google Scholar]
  3. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E. J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 1995 May 27;345(8961):1342–1344. doi: 10.1016/s0140-6736(95)92540-6. [DOI] [PubMed] [Google Scholar]
  4. Arnold G. F., Resnick D. A., Smith A. D., Geisler S. C., Holmes A. K., Arnold E. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology. 1996;39(1-2):72–78. doi: 10.1159/000150477. [DOI] [PubMed] [Google Scholar]
  5. Baba T. W., Trichel A. M., An L., Liska V., Martin L. N., Murphey-Corb M., Ruprecht R. M. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science. 1996 Jun 7;272(5267):1486–1489. doi: 10.1126/science.272.5267.1486. [DOI] [PubMed] [Google Scholar]
  6. Boyer J. D., Ugen K. E., Wang B., Agadjanyan M., Gilbert L., Bagarazzi M. L., Chattergoon M., Frost P., Javadian A., Williams W. V. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med. 1997 May;3(5):526–532. doi: 10.1038/nm0597-526. [DOI] [PubMed] [Google Scholar]
  7. Chakrabarti B. K., Maitra R. K., Ma X. Z., Kestler H. W. A candidate live inactivatable attenuated vaccine for AIDS. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9810–9815. doi: 10.1073/pnas.93.18.9810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  9. Deacon N. J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D. J., McPhee D. A., Greenway A. L., Ellett A., Chatfield C. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995 Nov 10;270(5238):988–991. doi: 10.1126/science.270.5238.988. [DOI] [PubMed] [Google Scholar]
  10. Deeks S. G., Smith M., Holodniy M., Kahn J. O. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 8;277(2):145–153. [PubMed] [Google Scholar]
  11. Ferrari G., Humphrey W., McElrath M. J., Excler J. L., Duliege A. M., Clements M. L., Corey L. C., Bolognesi D. P., Weinhold K. J. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396–1401. doi: 10.1073/pnas.94.4.1396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol. 1995 Feb;17(2):79–83. doi: 10.1016/0192-0561(94)00090-b. [DOI] [PubMed] [Google Scholar]
  13. Ghiara J. B., Ferguson D. C., Satterthwait A. C., Dyson H. J., Wilson I. A. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol. 1997 Feb 14;266(1):31–39. doi: 10.1006/jmbi.1996.0768. [DOI] [PubMed] [Google Scholar]
  14. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996 Jan 19;271(5247):324–328. doi: 10.1126/science.271.5247.324. [DOI] [PubMed] [Google Scholar]
  15. Honda M., Matsuo K., Nakasone T., Okamoto Y., Yoshizaki H., Kitamura K., Sugiura W., Watanabe K., Fukushima Y., Haga S. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10693–10697. doi: 10.1073/pnas.92.23.10693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hu S. L., Polacino P., Stallard V., Klaniecki J., Pennathur S., Travis B. M., Misher L., Kornas H., Langlois A. J., Morton W. R. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. Immunol Lett. 1996 Jun;51(1-2):115–119. doi: 10.1016/0165-2478(96)02564-3. [DOI] [PubMed] [Google Scholar]
  17. Igarashi T., Ami Y., Yamamoto H., Shibata R., Kuwata T., Mukai R., Shinohara K., Komatsu T., Adachi A., Hayami M. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. J Gen Virol. 1997 May;78(Pt 5):985–989. doi: 10.1099/0022-1317-78-5-985. [DOI] [PubMed] [Google Scholar]
  18. Kahn J. O., Steimer K. S., Baenziger J., Duliege A. M., Feinberg M., Elbeik T., Chesney M., Murcar N., Chernoff D., Sinangil F. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J Infect Dis. 1995 May;171(5):1343–1347. doi: 10.1093/infdis/171.5.1343. [DOI] [PubMed] [Google Scholar]
  19. Kestler H. W., Chakrabarti B. K. A live-virus "suicide" vaccine for human immunodeficiency virus. Cleve Clin J Med. 1997 May;64(5):269–274. doi: 10.3949/ccjm.64.5.269. [DOI] [PubMed] [Google Scholar]
  20. Levine A. M., Groshen S., Allen J., Munson K. M., Carlo D. J., Daigle A. E., Ferre F., Jensen F. C., Richieri S. P., Trauger R. J. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 1;11(4):351–364. doi: 10.1097/00042560-199604010-00005. [DOI] [PubMed] [Google Scholar]
  21. Lubeck M. D., Natuk R., Myagkikh M., Kalyan N., Aldrich K., Sinangil F., Alipanah S., Murthy S. C., Chanda P. K., Nigida S. M., Jr Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med. 1997 Jun;3(6):651–658. doi: 10.1038/nm0697-651. [DOI] [PubMed] [Google Scholar]
  22. McKinney R. E., Jr Antiretroviral therapy: evaluating the new era in HIV treatment. Adv Pediatr Infect Dis. 1996;12:297–323. [PubMed] [Google Scholar]
  23. Montgomery D. L., Shiver J. W., Leander K. R., Perry H. C., Friedman A., Martinez D., Ulmer J. B., Donnelly J. J., Liu M. A. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 1993 Nov;12(9):777–783. doi: 10.1089/dna.1993.12.777. [DOI] [PubMed] [Google Scholar]
  24. Race E., Frezza P., Stephens D. M., Davis D., Polyanskaya N., Cranage M., Oxford J. S. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses. Vaccine. 1995 Jan;13(1):54–60. doi: 10.1016/0264-410x(95)80011-2. [DOI] [PubMed] [Google Scholar]
  25. Race E., Stein C. A., Wigg M. D., Baksh A., Addawe M., Frezza P., Oxford J. S. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine. Vaccine. 1995 Nov;13(16):1567–1575. doi: 10.1016/0264-410x(95)00086-g. [DOI] [PubMed] [Google Scholar]
  26. Stahl-Hennig C., Dittmer U., Nisslein T., Petry H., Jurkiewicz E., Fuchs D., Wachter H., Mätz-Rensing K., Kuhn E. M., Kaup F. J. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol. 1996 Dec;77(Pt 12):2969–2981. doi: 10.1099/0022-1317-77-12-2969. [DOI] [PubMed] [Google Scholar]
  27. Stott E. J., Chan W. L., Mills K. H., Page M., Taffs F., Cranage M., Greenaway P., Kitchin P. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 1990 Dec 22;336(8730):1538–1541. doi: 10.1016/0140-6736(90)93310-l. [DOI] [PubMed] [Google Scholar]
  28. Wang B., Dang K., Agadjanyan M. G., Srikantan V., Li F., Ugen K. E., Boyer J., Merva M., Williams W. V., Weiner D. B. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine. 1997 Jun;15(8):821–825. doi: 10.1016/s0264-410x(96)00259-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES